Positive Phase 2 or Phase 3 psilocybin data for a substance-use disorder indication (AUD or TUD) publishes or is presented by 2027-06-30.

By June 30, 2027, we'll likely see solid clinical trial results showing that psilocybin helps people quit alcohol (AUD, or alcohol use disorder) or tobacco (TUD, or tobacco use disorder). Several trials are already running and approaching the point where researchers will have enough data to report findings. If the results are positive, it would be the first strong scientific evidence that a psychedelic can treat addiction at the level regulators take seriously.

Active TUD and AUD trials in current signals show a maturing pipeline diversifying beyond depression. Trial timelines and readout windows make a positive efficacy disclosure plausible within 12 months.